Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-dose, Active-controlled Randomized Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 (RPH-104/L04018) Administered at Different Doses to Patients With Acute Gout Attack

NCT04067492 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT04067492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04067492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-dose, Active-controlled Randomized Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 (RPH-104/L04018) Administered at Different Doses to Patients With Acute Gout Attack
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Terminated
Start date
March 26, 2018
Completion date
May 12, 2020
Enrollment
47 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gout attack